Trial reportJournal of clinical laboratory analysis2007
Effect of infliximab on the glycosylation of IgG of patients with rheumatoid arthritis.
Trial report in Journal of clinical laboratory analysis, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 49 citations in OpenAlex.
- The association between plasma IgG N-glycosylation and viral encephalitis in children: a hospital-based case-control study.Italian journal of pediatrics · 2026Article
- IgG glycosylation dynamics in active lupus nephritis during the first year of immunosuppressive therapy.Frontiers in immunology · 2026Article
- Immunoglobulin G N-Glycosylation and Inflammatory Factors: Analysis of Biomarkers for the Diagnosis of Moyamoya Disease.Journal of inflammation research · 2025Article
- The role of antibody glycosylation in autoimmune and alloimmune kidney diseases.Nature reviews. Nephrology · 2024Review
- Tailored therapeutic decision of rheumatoid arthritis using proteomic strategies: how to start and when to stop?Clinical proteomics · 2023Review
- Anti-TNF Biologicals Enhance the Anti-Inflammatory Properties of IgG N-Glycome in Crohn's Disease.Biomolecules · 2023Article
- Distinct Longitudinal Changes in Immunoglobulin G N-Glycosylation Associate with Therapy Response in Chronic Inflammatory Diseases.International journal of molecular sciences · 2022Article
- Immunoglobulin G N-glycan Biomarkers for Autoimmune Diseases: Current State and a Glycoinformatics Perspective.International journal of molecular sciences · 2022Review
- Changes of IgGFrontiers in immunology · 2022Article
- Immunoglobulin G Glycosylation in Diseases.Experientia supplementum (2012) · 2021Article
- Ig Glycosylation in Ulcerative Colitis: It's Time for New Biomarkers.Frontiers in pharmacology · 2021Article
- Glycosylation in Autoimmune Diseases.Advances in experimental medicine and biology · 2021Article
- Immunoglobulin G Glycosylation Changes in Aging and Other Inflammatory Conditions.Experientia supplementum (2012) · 2021Article
- Rheumatoid Arthritis in the View of Osteoimmunology.Biomolecules · 2020Review
- Sialylated Immunoglobulins for the Treatment of Immuno-Inflammatory Diseases.International journal of molecular sciences · 2020Review
- Estrogen induces St6gal1 expression and increases IgG sialylation in mice and patients with rheumatoid arthritis: a potential explanation for the increased risk of rheumatoid arthritis in postmenopausal women.Arthritis research & therapy · 2018Article
- Hypogalactosylation of immunoglobulin G in rheumatoid arthritis: relationship to HLA-DRB1 shared epitope, anticitrullinated protein antibodies, rheumatoid factor, and correlation with inflammatory activity.Arthritis research & therapy · 2018Article
- The B cell response to citrullinated antigens in the development of rheumatoid arthritis.Nature reviews. Rheumatology · 2018Review
- The Role of Posttranslational Protein Modifications in Rheumatological Diseases: Focus on Rheumatoid Arthritis.Journal of immunology research · 2015Review
- IgG-Fc N-glycosylation at Asn297 and IgA O-glycosylation in the hinge region in health and disease.Glycoconjugate journal · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In patients with rheumatoid arthritis (RA) a decrease in the terminal galactose content of N-linked glycans of the Fc region of agalactosyl immunoglobulin G (IgG) (G0) occurs. The aim of this study was to evaluate, for the first time, the effect of infliximab, a new monoclonal antibody for the treatment of RA, on this phenomenon. A total of 19 patients with active RA were treated with intravenous infliximab (3 mg/kg) in combination with methotrexate (MTX) (10-20 mg). IgG was purified from their serum by caprylic acid. Analysis of IgG glycosylation was performed by lectin blotting/immunoblotting and enzyme linked lectin assay (ELLA)/enzyme linked immunosorbent assay (ELISA) using the Griffonia (bandeiraea) simplicifolia lectin II and protein-A/alkaline phosphatase. The purity of IgG samples obtained was higher than 90%. The sensitivity of the lectin/immunoblotting method was of about 0.25 microg of IgG. The inter- and intraassay coefficients of variation (CV) were 1.3% and 9.0% for lectin blotting, and 4.6% and 8.3% for immunoblotting, respectively. The sensitivity of the ELLA/ELISA approach was 0.025 microg/microL and the inter- and intraassay CV were 6.2% and 7.7% for ELLA, and 5.1% and 14.1% for ELISA, respectively. A good linear correlation (r2=0.18, P<0.05) was obtained between the two different experimental approaches. A decrease of G0 was observed in patients who clinically improved (according to the American College of Rheumatology criteria) following the pharmacological treatment. Our data indicate that infliximab can reduce the concentration of G0 in patients with active RA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.